CAC Nantong Chemical Co - Public Comps and Valuation Multiples

CAC Nantong Chemical Co Overview

About CAC Nantong Chemical Co

CAC Nantong Chemical Co Ltd is engaged in Research and development, production and sales of pesticide products and functional chemicals.

Founded

2004

HQ

Employees

n/a

Website

cacch.com

Sectors

Chemicals

Financials

Last FY Revenue $595M

Last FY EBITDA $88.5M

EV

$1.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

CAC Nantong Chemical Co Financials

See CAC Nantong Chemical Co valuation multiples based on analyst estimates

CAC Nantong Chemical Co P&L

In the most recent fiscal year, CAC Nantong Chemical Co reported revenue of $595M and EBITDA of $88.5M.

CAC Nantong Chemical Co expects next 12-month revenue of XXX and NTM EBITDA of XXX

See CAC Nantong Chemical Co valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$595M	XXX	XXX	XXX
Gross Profit	XXX	$125M	XXX	XXX	XXX
Gross Margin	XXX	21%	XXX	XXX	XXX
EBITDA	XXX	$88.5M	XXX	XXX	XXX
EBITDA Margin	XXX	15%	XXX	XXX	XXX
EBIT	XXX	$57.6M	XXX	XXX	XXX
EBIT Margin	XXX	10%	XXX	XXX	XXX
Net Profit	XXX	$37.4M	XXX	XXX	XXX
Net Margin	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	$87.0M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for CAC Nantong Chemical Co including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, CAC Nantong Chemical Co achieved $595M in revenue and $88.5M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$595M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$125M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	21.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$88.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	14.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$57.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	9.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$37.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	6.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$87.0M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for CAC Nantong Chemical Co

This financial data table provides comprehensive performance metrics for CAC Nantong Chemical Co, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, CAC Nantong Chemical Co reported $595M in total revenue.
Fiscal year EBITDA was $88.5M.
The company maintained a gross profit margin of 21.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.9%.
Net profit margin reached 6.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for CAC Nantong Chemical Co. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

CAC Nantong Chemical Co Stock Performance

CAC Nantong Chemical Co has current market cap of CNY 13.1B (or $1.8B), and EV of CNY 13.8B (or $1.9B).

Market Cap Evolution

CAC Nantong Chemical Co Stock Data

As of October 7, 2025, CAC Nantong Chemical Co's stock price is CNY 29 (or $4).

See CAC Nantong Chemical Co trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.9B	$1.8B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

CAC Nantong Chemical Co Valuation Multiples

CAC Nantong Chemical Co's trades at 3.3x EV/Revenue multiple, and 21.9x EV/EBITDA.

See valuation multiples for CAC Nantong Chemical Co and 15K+ public comps

CAC Nantong Chemical Co Financial Valuation Multiples

As of October 7, 2025, CAC Nantong Chemical Co has market cap of $1.8B and EV of $1.9B.

Equity research analysts estimate CAC Nantong Chemical Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CAC Nantong Chemical Co's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.8B	XXX	$1.8B	XXX	XXX	XXX
EV (current)	$1.9B	XXX	$1.9B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	3.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	21.9x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	33.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	49.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-24.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CAC Nantong Chemical Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

CAC Nantong Chemical Co Margins & Growth Rates

CAC Nantong Chemical Co's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

CAC Nantong Chemical Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CAC Nantong Chemical Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for CAC Nantong Chemical Co and other 15K+ public comps

CAC Nantong Chemical Co Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	15%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	11%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial